Immunodominant T cell epitopes of myelin basic protein (MBP) may be target antigens for major histocompatibility complex class II-restricted, autoreactive T cells in multiple sclerosis (MS). Since susceptibility to MS is associated with the DR2 haplotype, the binding and presentation of the immunodominant MBP(84-102) peptide by DR2 antigens were examined. The immunodominant MBP(84-102) peptide was found to bind with high affinity to DRB1*1501 and DRB5*0101 molecules of the disease-associated DR2 haplotype. Overlapping but distinct peptide segments were critical for binding to these molecules; hydrophobic residues (Va1189 and Phe92) in the MBP(88-95) segment were critical for peptide binding to DRBl*1501 molecules, whereas hydrophobic and charged residues (Phe92, Lys93) in the MBP(89-101/102) sequence contributed to DRB5*0101 binding. The different registers for peptide binding made different peptide side chains available for interaction with the T cell receptor. Although the peptide was bound with high affinity by both DRB1 and DRB5 molecules, only DRB1 (DRB1*1501 and 1602) but not DRB5 molecules served as restriction elements for a panel of T cell clones generated from two MS patients suggesting that the complex of MBP(84-102) and DRB1 molecules is more immunogenic for MBP reactive T cells. The minimal MBP peptide epitope for several T cell clones and the residues important for binding to DRBl*1501 molecules and for T cell stimulation have been defined.
S
usceptibility to a variety of human autoimmune diseases is associated with alleles of MHC class I or class II genes. Examples of autoimmune diseases associated with MHC class II haplotypes include insulin dependent diabetes (DR3 and DR4 haplotypes), myasthenia gravis (DR3) and multiple sclerosis (DR2) (1-3). The major hypothesis is that these allelic gene products define the specificity of an immune attack against self-antigens by presentation of tissue specific selfpeptides to T cells.
In the case of multiple sclerosis (MS)} this hypothesis implies that DR2 antigens (either DRB1*1501 or DRB5*0101 molecules encoded in the DR2 haplotype, or both) present self-peptides(s) from a myelin/oligodendrocyte antigen since the disease is restricted to the white matter of the central but not peripheral nervous system. Based on their encephalitogenicity in animal models (4) (5) (6) , myelin basic pro-1 Abbreviations used in this paper: MBP, myelin basic protein; MNC, mononuclear cells; MS, multiple sclerosis; PLP, proteolipid protein.
tein (MBP) and proteolipid protein (PLP) have long been viewed as the principal candidate antigens. The role of MBP and PLP reactive T ceils in the pathogenesis of MS has, however, been difficult to prove.
In animal models, encephalomyelitis is mediated by T cells reactive with immunodominant determinants of MBP or PLP (4) (5) (6) . In humans, two dominant T cell epitopes are located in the center and in the COOH-terminal portion of the molecule [MBP(84-102) and MBP(143-168)] (7-10). These epitopes may be relevant to the pathogenesis of MS since both peptides can be presented by DRBl*1501 and DRB5*0101 molecules of the disease associated haplotype. DRBl*1501 molecules present MBP(80-99) and MBP(148-162) peptides; MBP(87-106), MBP(131-145), MBP(139-153), and MBP(76-91) are presented by the DRBS*0101 molecule (8, 9) . A number of other DR and DQ antigens can also serve as restriction elements, in particular for T cells reactive with the MBP(87-106) peptide (11, 12) .
The analysis of structural requirements for the interaction of MBP peptides with MHC class II antigens, in particular with the MS associated DR2 isotypes (DRBl*1501 and DRB5*0101, sometimes also referred to as DR2b and DR2a, respectively), may help to define the biochemical basis for the association of DR2 with MS. The present data demonstrate that DtLBl*1501 and DRB5*0101 molecules interact with different residues of the MBP(84-102) peptide. The MBP(84-102) peptide complexed with DRBl*1501 and DRBl*1602 molecules appears to generate a more vigorous immune response since MBP(84-102)-specific, DR-restricted T cell clones examined in the present study were restricted by DRB1*1501 or DRB1*1602 (a closely related DR2 allele) and not by DRB5*0101 molecules.
Materials and Methods

Cloning of MBP(84-102)-specific T Cells. MBP-specific T cell lines
were generated from blood mononuclear cells as previously described (7) . Briefly, mononuclear cells (MNC) from two MS patients were cultured with purified human MBP (100 #g/ml) in RPMI 1640 supplemented with 10% pooled human serum, 2 mM t-glutamine, 10 mM Hepes, 100 U/100 #g per ml penicillin/streptomycin in 96-well plates at 2 x 10 s cells/well. On day 3, IL-2 was added to 5% Human T-Stim (Becton Dickinson & Co., Mountain View, CA) and cells were fed with media containing 5% II.-2 every 3-4 d. On day 14, an aliquot of each cell line was assayed for reactivity to human MBP. 104 cells from each T cell line were cocultured with 104 irradiated autologous MNC in duplicate for 72 h; a [3H]thymidine pulse was done during the last 18 h of culture. MNC were prepared by pulsing cells with or without 100 kcg/ml of MBP for I h at 37~ MBP-specific T cell lines (stimulation index >3) were retested using a panel of 13 synthetic peptides encompassing the human MBP sequence. MBP-specific T cell lines were maintained by restimulation with MBP or peptide pulsed MNC at 10-14-d intervals. Following a third round of stimulation (generally two stimulations with MBP and one stimulation with peptide), T cell lines were cloned by limiting dilution using allogeneic feeder cells and phytohemagglutinin (1 #g/ml) (Murex Diagnostics, Dartford, UK) for stimulation. Allogeneic MNC were irradiated with 5,000 rad and co-cultured in 96-well plates (10 s cells/well) with T cells (0. To further define the MHC restriction of DR-restricted T cell clones, L cell transfectants expressing DRB1*1501, DRB5*0101, and DRBI*0401 molecules (a kind gift of Dr. R. Sekaly, Institut de Recherches Cliniques de Montreal, Canada) were used. L cell transfectants were grown in RPMI 1640 supplemented with 10% FCS, 2 mM r-glutamine, 10 mM Hepes, 100 U/100 #g per ml penicillin/streptomycin as well as mycophenolic acid (6 #g/ml), xanthine (250/zg/ml), and hypoxanthine (15/~g/ml). Cell surface expression of DR molecules was verified by FACS | analysis (Becton Dickinson & Co.). For T cell stimulation assays, L cell transfectants were scraped from plates, washed, irradiated (5,000 tad), and pulsed with the MBP(84-102) peptide at a concentration of 50 #M for 2 h at 37~ After the peptide pulse, cells were washed and co-cultured with T cells in triplicates for 3 d (2.5 x 104 L cells and 5 x 104 T cells/well of a 96-well plate). T cell proliferation was measured as [3H]thymidine incorporation after an 18-h pulse. DR molecules were purified essentially as described by Gorga et al. (13) using the mAb LB3.1 covalently coupled to protein A-Sepharose CL-4B. Aliquots of cell lysate equivalent to ,o10 g of cells were passed sequentially through the following columns: Sepharose CL-4B (10 ml), and LB3.1-protein A-Sepharose (15 ml) using a flow rate of 15 ml/h. The columns were washed with 10-column volumes of 10 mM Tris-HC1, pH 8.0, 0.1% Renex (5 ml/h); 2-column volumes of PBS, and 2-column volumes of PBS, 1% octylglucoside. DR molecules were eluted from the LB3.1 column with 0.05 M diethylamine, in 0.15 M NaC1 containing 1% octylglucoside (pH 11.5), immediately neutralized with 2 M glycine, pH 2.0, and concentrated by ultrafiltration through a membrane
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Peptide Presentation by HLA-DR2 Binding of hMBP Peptides to Purified HLA Class II Molecules. Purified DR molecules (5-500 nM) were incubated with 5-nM 125I-radiolabeled peptides for 48 h in PBS containing 5% DMSO in the presence of a protease inhibitor mixture. Purified peptides were iodinated using the chloramine T method. The final concentrations ofprotease inhibitors were: 1 mM PMSF, 1.3 mM 1.10 phenanthroline, 73 #M pepstatin A, 8 mM EDTA, 6 mM N-ethylmaleimide, and 200 /~M N-tosyl-t-phenylalanine chloromethyl ketone (TLCK). Final detergent concentration in the incubation mixture was 0.05% NP-40. Assays were performed at pH 7.0. The DR-peptide complexes were separated from free peptides by gel filtration in Sephadex G50 columns as previously described or TSK2000 column (7.8 mm x 15 cm) eluted at 1.2 ml/min in PBS, pH 6.5, containing 0.5% NP40 and 0.1% NAN3. Because the large size of the radiolabeled peptide used for the DRBI*1501 binding assay makes separation of bound from unbound peaks more difficult under these conditions, all DRBI*1501 assays were performed using a TSK2000 (7.8 mm x 30 cm) column eluted at 0.6 ml/min. Column eluates were passed through a radioisotope detector (model 170; Beckman Instruments, Fullerton, CA), and radioactivity was plotted and integrated with an integrator (model 3396A; Hewlett-Packard Co., Palo Alto, CA). The fraction of peptide bound was determined as previously described. The radiolabeled peptides were: hMBP Y80-103 for DRBI*1501 and TT 830-843 for DRB5*0101. In preliminary experiments, each of the DR preparations was titered in the presence of fixed amounts of radiolabeled peptides to determine the concentration of DR molecules necessary to bind 10-20% of the total radioactivity. All inhibition assays were performed using these DR concentrations and inhibitory peptides were typically tested at concentrations ranging from 120/xg/ml to 1.2 ng/ml. The data were then blotted and the dose yielding 50% inhibition determined. Each peptide was tested in two to four independent experiments and results are presented as arithmetic mean of binding capacity expressed as nanomolar. To allow for a better comparison of data obtained in different experiments, in each experiment a binding figure relative to a known binder (ratio to standard) was calculated. The ratio to standard was determined in the following way: the 50% inhibition doses (nM) for standard peptides [MBP Y(80-103) for DRB1*1501 and TT(830-843) for DRBS*0101] were divided by the 50% inhibition doses (nM) for each test peptide. The ratios shown in Table  4 are the mean of two to four independent experiments.
Results
Presentation of the MBP(84-102) Peptide by DRBI*lSO1
Molecules of the DR2 Haplotype. MBP-specific T cell lines were generated from blood mononuclear cells of two patients with MS and tested for their epitope specificity using a panel of overlapping synthetic MBP peptides (7). After two rounds of stimulation with antigen and one stimulation with the MBP(84-102) peptide, lines were cloned by limiting dilution using PHA, IL-2, and allogeneic feeder cells. By serological typing patients were classified as DR2/DR4 (patient (14) . Therefore, L cell transfectants expressing DRBl*1501 or DRB5*0101 molecules were used as antigen presenting cells for T cell clones that proliferated in response to peptide pulsed B cell line 9010 (homozygous for the DRBl*1501 haplotype). All MBP(84-102)-specific T cell clones tested proliferated in response to the MBP(84-102) peptide when presented by DRBl*1501 but not by DRB5*0101 molecules (Table 1) .
Two other MBP(84-102)-specific T cell clones from patient Hy (DR2, DR7/DQ1, DQ3) were HLA-DQ restricted since the proliferative response was blocked by mAb $3/4. Both T cell clones are DQl-restricted and recognize the peptide presented by BCL that express DQ1 (9001: DR1/DQ1, 9009: DR2/DQ1) but not by a BCL that expresses DQ6 (9010: DR2/DQ6) ( Table 2 ). The DR.l-associated DQ1 molecule (DQAI*0101-DQBI*0501) has only two amino acid differences (DQot34, DRy57) from the DR2-associated DQ1 molecule (DQAI*0102-DQBI*0502) that apparently to not affect presentation of the peptide (14) .
A 14-.,4 mino Acid Peptide, MBP(85-98) Is Required for Efficient Stimulation of the Majority of DRBl*15Ol-restricted T Cell
Clones. Peptides recognized by MHC class I antigens have strict length requirements (8-10-mer) (15) (16) (17) (18) ; truncation or addition of a single residue has a profound effect on peptide binding to class I molecules. In contrast, naturally processed peptides bound to class II antigens were found to be longer and more heterogeneous in size (13-25 residues in the case of HLA-DR1 bound peptides) (19) (20) (21) . Whereas short peptides can bind with high affinity to MHC class II molecules (e.g., hen egg lysozyme, residues 52-61 to I-A k) (22) , longer peptides may be required for recognition by at least some T cell receptor molecules. Therefore, a set of synthetic peptides with successive truncations at either the NH2 or the COOH terminus of MBP(84-102) was used to define the minimal T cell epitope of MBP(84-102) among DRBI* 1501-restricted T cell clones. To compare the relative efficiency of peptides with respect to T cell stimulation, a homozygous BCL (9010, DR2/DQ6) was pulsed with peptides at concentrations ranging from 5 nM to 50/zM. From these titration curves, the peptide concentration required for 50% max- Table 3) . There was a substantial loss of T cell reactivity in five of eight clones with an NH2-terminal truncation of Glu85; three other clones tolerated truncation of Glu85 and Ash86 without a major loss of reactivity. In contrast, truncation at the COOH terminus to residue 97 greatly diminished the response by all clones. While two of the eight clones recognized peptides with further COOH-terminal truncations (truncation up to residue 95/96), high peptide concentrations were required for stimulation. Synthetic peptides truncated at both the NH2 and the COOH terminus demonstrated that residue 99 was not required for seven of eight clones; however, clone Hy.2Ell required 53 times more peptide for 50% maximum stimulation when peptide (86-98) rather than (86-99) was used (Table 3) . These results indicate that all MBP(84-102) specific clones share a MBP(87-97) core determinant but that they are heterogeneous with respect to peptide length requirements at the NH2 or COOH terminus. For the majority of clones, a MBP(85-98) peptide (a 14-mer) gave optimal stimulation, however, shorter pep- tides (12-and 13-mer) were sufficient for two other clones. Therefore, 12-14-amino acid peptides appear to be required for efficient recognition by class II restricted T cell receptors; the size distribution of naturally processed peptides from the class II pathway reflects this requirement (23) .
A 25-Amino Acid Peptide Stimulates T Cells as Efficiently as a 14-A mino Acid
Peptide. The isolation of nested sets of naturally processed peptides suggested that the peptide binding groove of class II molecules is open at both ends (19) (20) (21) ; this notion was confirmed by the crystal structure of HLA-DR1 (24) . However, NH2-or COOH-terminal extensions beyond a certain size may interfere with binding to MHC class II molecules or with TCR recognition. Therefore, T cell stimulation by 14-25-amino acid peptides was compared. As demonstrated in Fig. 1, T (Table  4) ; these peptides served as standards in the peptide competition assay. The MBP(84-102) peptide bound to DRB1*1501 and DRBS*0101 molecules with high affinity (ICs0 for DRB1*1501:4.2 nM; IC50 for DRB5*0101:55 nM). Truncation of Va189 and Ile95 at the NH2 and COOH terminus, respectively, reduced the binding affinity to DRBl*1501 molecules 10.5-and 67-fold. In contrast, truncation of the two COOH-terminal proline residues (101 + 102) greatly diminished the affinity of the peptide binding to DRB5*0101 molecules; truncation of I1e95 abolished binding (Table 4 A). Thus, the peptide core sequences required for binding to DRB1*1501 and DRB5*0101 molecules overlap, but are not identical (residues 88-95 for binding to DRBl*1501 and a sequence within 89-101/102 for binding to DRB5*0101 molecules).
A set of analog peptides with single amino acid substitutions was" used to further define peptide side chains critical for binding to DR2 molecules. Substitution of Va189 and Phe92 by alanine greatly diminished the peptide binding affinity to DRB1*1501 molecules while alanine substitution of Phe92, Lys93 and possibly Arg99 affected binding to DRB5*0101 molecules (Table 4 B ). The side chain specificity requirements were further examined by introducing charged or aromatic residues at positions 88, 89, 92, or 95 (Fig. 2) . A negatively charged residue (aspartic acid) was not tolerated at positions 88, 89, or 92 suggesting that the corresponding DR "pockets" represent a hydrophobic environment. A large aromatic residue (tryptophan) could be placed at position 92 while replacement of Va188 or Va189 by phenylalanine resulted in a complete or partial loss of T cell recognition, respectively (Fig. 2) . The decreased binding affinity after truncation of Ile95 probably reflects an important contact of the peptide backbone rather than a peptide side chain with the DR molecule as substitutions by both aspartic acid and tryptophan were tolerated (Fig. 2) .
Phe91 Is a Critical T Cell Receptor Contact Point for All MBP(84-IO2)-specific T Cell Clones.
While only residues in the MBP(88-95) core sequence contributed significantly to binding of the peptide to DRB1*1501 molecules, TCR recognition of the peptide required residues 85-87. The presence of Pro87 was sufficient for stimulation of two T cell clones; all other clones, however, required also Glu85 + Ash86 or Asn86. Residues COOH-terminal to Ile95 were apparently not essential for binding of the peptide; however, Thr97 and Pro98 were critical for TCR recognition since a MBP(84-96) peptide had only minimal or no activity in the T cell proliferation assay. Even though residues 85-87 and 96-98 could not be truncated, substitution of the peptide side chains by alanine had no major effect on T cell recognition suggesting that the TCR makes essential contacts
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Peptide Presentation by HLA-DR2 Radiolabeled MBP Y(80-103) and TT(830-843) peptides were used as probes for afhnity purified DRB1 "1501 and DRB5"0101 molecules; unlabeled analogs of MBP(84-102) were used as competitors for radiolabeled peptide. Each peptide was tested in two to four independent experiments and results are represented as arithmetic mean of binding capacity expressed in nM. Peptide concentration (itM) MHC binding. Peptide residues that contribute to binding based on the analysis of alanine analogs in a direct binding assay are indicated in bold; an analysis of analog peptides (substitution of Va188 by a charged or aromatic residue) in a T cell stimulation assay also indicated that Va188 contributes to peptide binding to DRB1*1501 molecules. TCR recognition. Peptide segments required for optimal stimulation of T cell clones are indicated, residues that are putative TCR contacts are highlighted if an alanine analog gave minimal or no T cell stimulation. For secondary TCR contacts, a significant decrease in T cell reactivity was seen (in general, >100-fold higher peptide concentrations were required for a response equivalent to the MBP(85-99) peptide).
tide to a "motif" (25, 26) . Alignment of the MBP(85-99) peptide with a second determinant, MBP(148-162), presented by DRBl*1501 molecules also reveals structural similarities in the center of the peptides. Both peptides have aliphatic residues (i) and a large hydrophobic residue with the same spacing [aliphatic (i), large hydrophobic (i + 3)]. In addition, valine and threonine at position i-1 are isosteric (Table 7) .
Discussion
Immunodominant T cell epitopes of myelin basic protein and proteolipid protein may be target antigens for autoaggresfive T cells in MS (27) . The immunodominant MBP(84-102) peptide was found to bind with high affinity to DIL81*1501 and DRB5*0101 molecules of the disease associated DR2 haplotype. Overlapping but distinct peptide segments are critical for binding to these molecules: Hydrophobic residues (Val89 and Phe92) in the MBP(88-95) segment are critical for peptide binding to DRBl*1501 molecules while hydrophobic and charged residues (Phe92, Lys93) in the MBP-(89-101/102) sequence contribute to DRB5*0101 binding.
The MBP(90-102) peptide was previously found to be presented by DRB5*0101, DRBI*0401, DIL81*0404, and DRBl*1302 molecules (DR2a, DR4 Dw4, DR4 Dw14, DR13 Dw19); the DRB5*0101-restricted T cell clone could also recognize a MBP(92-102) peptide (11) . These T cell data are consistent with the peptide binding experiments that demonstrate that Phe92, Lys93, and Pro101/102 contribute to DRB5*0101 binding. Alanine substitutions of residues Asn94, 287 Wucherpfennig et al.
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, and Arg99 (which do not appear to contribute to peptide binding) abolished T cell recognition of the MBP(89-100) peptide indicating that these residues are likely TCR contact residues (28) . The different peptide reading frames in the two MHC molecules make different peptide residues available for contact with the TCR: Lys93 was found to be an important TCR contact residue for DRBI* 1501 restricted T cell clones but a DR contact residue for DRBS*0101 molecules (Table 6) . What is the structural basis for the different registers in which MBP(84-102) is bound to DRB1*1501 and DRBS*0101 molecules? The differential binding can in part be attributed to the Gly/Val dimorphism at position 86 of the DR3 chain that controls the size of a major hydrophobic pocket created by DRot chain residues Phe26 and Ile31 (24, 29, 30) . As DR386 is a glycine in DRB5*0101 molecules sufficient space is available for an aromatic anchor residue (Phe92 of the MBP peptide). In contrast, the presence of valine at DR386 in DRBI* 1501 molecules results in selection of a smaller aliphatic anchor residue, most likely Va189 of the MBP peptide. The adjacent residue (Va188) probably also resides in a hydrophobic environment as substitution by aspartic acid is not tolerated (Fig. 2) . T cell stimulation data (Fig. 2) indicate, however, that an analog peptide with an aromatic side chain (Va189 substituted by Phe) can also be presented by DRBl*1501 molecules, albeit less efficiently. Therefore, other polymorphic residues in the cleft are likely to be involved in the selection of the peptide reading frame, possibly by not allowing particular residues (because of charge or size) at a given peptide position. In this respect, the most striking difference between DtLB1*1501 and DRB5*0101 molecules is the presence of a cluster of aspartic acid residues in DR.B5*0101 molecules (DKB residues 11, 30, 37, and 70) which make the cleft considerably more acidic than in DRBl*1501 molecules. In contrast, a cluster of hydrophobic residues is present in DR.Bl*1501 molecules (DR/3 residues Trp9, Pro11, Tyr30, Phe31, and Tyr32). The MBP(86-105) peptide binds to DRBI*0101, DRBI*0401, DR.BI*0404, DRBI*0701, DRBl*1101, and DRBI* 1501 molecules but fails to interact with DRBI*0301 molecules (31) . DRBI*0301 molecules may recognize a distinct peptide motif (aliphatic at position i, hydrogen bond donor at position i+3) (32, 33) , criteria which are not met by the MBP(84-102) peptide as an aromatic residue (Phe) would be at i+ 3 if either Va188 or Va189 was placed at position i. Peptide binding motifs for DR1 specify an aromatic residue (predominantly Tyr and Phe but also Trp) at position i, with additional constraints (mostly hydrophobic amino acids) at positions i+3, i+5, and i+8 (34) (35) (36) (37) (38) . Binding of the MBP(84-102) peptide to DR1 which also has a glycine residue at DR/386 therefore probably involves Phe92 (i) and Ile95 (i+3), residues that are also involved in DRB5*0101 binding. In contrast to DRB5*0101, binding to DRBI*0101 molecules is unlikely to involve Lys93.
The detailed structural analysis of an immunodominant, encephalitogenic MBP peptide (Acl-9) presented by I-A u molecules allowed MHC and TCR. contact points to be identified and nonstimulatory blocking peptides to be designed. Substitution of Gin and Lys (residues 3 and 4) resulted in a potent blocking peptide for Acl-11-specific T cells (39) . The distinct requirements for peptide binding to DRB1*1501 and DR.B5*0101 molecules may therefore allow blocking agents to be developed that selectively interfere with autoantigen presentation by either DRBI* 1501 or DRB5*0101 molecules. Furthermore, an understanding of the structural features that result in high affinity binding of self-peptides by different DR2 molecules may aid in the identification of other encephalitogenic peptides involved in the immunopathogenesis of MS.
Clinical trials that demonstrate a therapeutic benefit from deletion/tolerization of MBP-specific T cells in MS patients are, however, required to prove the role of MBP peptides (or other self-peptides) in the immunopathogenesis of MS (27) .
